The $ 20 million bet on CRISPR to cure rare teething problems

Rare genetic diseases are a challenge for patients and their families – have made all the overwhelming because symptoms tend to appear shortly after birth.

To date, there have not been many reliable treatment options for these babies. The few who do exist include invasive and risky procedures that do not often have a high success.

But there is a new source of hope for many of these families: the Center for Pediatric Crisper Cures at the University of California San Francisco. The Center Plan for which it was announced on 8 July a collaboration between Jennifer Doudna, director of the Innovative Genomics Institute at the University of California, Berkeley, who also earned the Nobel Prize for its work in Co-Co-Co-Ceo and coan founder of the Chan Zuckerberg initiative.

Supported by $ 20 million from the Chan Zuckerberg Initiative, the center focuses on the treatment of rare genetic diseases in children, starting with a group of eight children who will register for a clinical study to gain access to a CRISPR therapy specially designed for them. Doctors and researchers, including Chan and Doudna, believe that CRISPR can be used to change and correct a series of genetic mutations and scaled up to help more patients. And the medical teams are planning to register patients immediately.

“We want to ensure that CRISPR -based therapies become available on a large scale, especially for rare diseases that are probably not the target for pharmaceutical companies,” Doudna tells Time.

Read more: The 4 words that drive your doctor the wall

The collaboration was inspired by the recent success in the treatment of KJ Muldoon, the first baby to receive a customized CRISPR treatment. KJ was born in the children’s hospital of Philadelphia with a rare genetic disease that prevents him from breaking proteins well. The therapy, called base editing, replaced a defective letter in KJ’s DNA with the right one that now lets him eat some protein.

KJ’s treatment represents the next phase of CRISPR -based therapies. While CRISPR treatments have been approved by the FDA to treat sickle cell disease and Certain types of beta thalassemiaThese therapies include the removal of patients’ cells, the editing of CRISPR to correct the genetic defect and then bring those cells back to the patients. In the case of KJ, the CRISPR processing took place in its own body, through three injections of a therapy that only developed for him. That is the same model that the new center will use.

“With that story there was a lot of momentum within our teams about whether we could do that again, and how we could learn to create a pipeline to lower the costs and make this therapy much more widely available,” says Doudna.

Doudna thought of Chan, whose initiative the mission From healing, preventing or treating all diseases against the end of the century. It was an ideal competition because Chan had trained as a pediatrician at the University of California San Francisco and treated children with rare genetic diseases for eight years after completing the medical school.

“When Jennifer called me, I thought:” This is perfect, “says Chan De Tijd. She remembers that they encountered families whose babies were struck by diseases that were so rare that there was often little or no information about them.” I have in my mind the image of a parent who put me a pdf that they have been doing to each resident. I carry that around every day. ”

The experience inspired her to create the rare as one program at the Chan Zuckerberg Initiative, a network of patients, researchers and scientists from different disciplines that are important for basic research needed to better understand these disorders to develop more effective treatments for them.

Read more: The surprising reason that national hospitals close

CRISPR, with its ability to focus on specific genetic mutations, is the most promise to change the course of such diseases. But time is essential. In the case of KJ, the entire process of identifying its mutation, the development of treatment, testing and receiving FDA declaration took nine months. KJ was only six months old when he received his first CRISPR treatment. Acts that are quickly crucial for such disorders, because as soon as cells or organs are damaged by pathogenic mutations, they cannot always be saved. The idea is to intervene with a CRISPR therapy to minimize the effects that the mutations could have.

Currently over 6,000 rare diseases Worldwide influences 300 million people and 72% of them are linked to genetic abnormalities. A similar part mainly affects children. The new center will focus on identifying pathogenic mutations that can easily be directed-as in the liver, as in the case of KJ. “Jennifer and her team, and the UCSF team, will be very careful when choosing mutations that are susceptible to this treatment,” says Chan. “Not all mutations will work well with this version of CRISPR … so there will be a delicate balance when choosing patients who benefit the most in this situation.”

Patients will participate in a clinical study to receive treatment, and the research team will study them to learn from their experiences and to continue to improve the treatment and the process.

Read more: Why it is so difficult to have your fertility tested

In the first cases that will try to treat the center, the FDA will consider each treatment itself and decide whether the adapted therapy is approved for that specific patient. But, says Doudna, “as we continue to get more information about the safety and potential risks of CRISPR for different indications, what is on the rise is the potential to indicate CRISPR as a platform technology.” This means that if regulators approve the framework of the CRISPR gene processing process, doctors do not have to perform animal testing for every new CRISPR therapy designed for a patient. The only thing that would change would be the guide, says Doudna, which carries the genetic instructions for finding the specific mutation to be tackled. “Even there, most of the guide -RNA remains the same, and it is just the piece at the end and offers the molecular zip code that changes.”